Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch
The FDA has come through with an approval for Valeant’s psoriasis drug brodalumab. But they’ve hobbled it with a black box safety warning on suicidal ideation and a risk mitigation marketing program that will likely hobble its revenue in an intensely competitive market.
An FDA panel already flagged through the drug — to be sold as Siliq — with many of the experts clearly more interested in obtaining another arrow for their quiver rather than the potential safety issues, which they felt were manageable.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.